Cytodyn can’t run all the trials they’d like at the size (locations, total patients) they’d like without a lot of money. Yes, an approval would likely generate quite a bit of money to fund some of that. But a partner for a single indication like NASH would accelerate our efforts because we don’t have an approval right now. All other programs (or at least the first four or five) benefit from the cash a partner infused. But I’m terms of share price we’d also benefit from the exposure and legitimacy a high profile partner brings. Pfizer, Gilead, J&J, and all the others would be singing from the mountain tops about their new partnership and that alone would do wonders to the share price through real, far-reaching awareness of CYDY and the little MAB that could. I say bring it on. But just for a single indication and do it soon.